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Angiogenesis and extracellular matrix degradation are key events in tumour progression, and factors regulating stromal–epithelial
interactions and matrix composition are potential targets for the development of novel anti-invasive/antiangiogenic therapies. Here,
we examine the expression of ADAMTS-8, a secreted protease with antiangiogenic properties, in brain tissues. Using quantitative RT–
polymerase chain reaction (PCR), high, equivalent expression of ADAMTS-8 was found in normal whole brain, cerebral cortex, frontal
lobe, cerebellum and meninges. ADAMTS-8 expression in 34 brain tumours (including 22 high-grade gliomas) and four glioma cell lines
indicated at least two-fold reduction in mRNA compared to normal whole brain in all neoplastic tissues, and no detectable
expression in 14 out of 34 (41%) tumours or four out of four (100%) cell lines. In contrast, differential expression of TSP1 and VEGF
was seen in nine out of 15 (60%) and seven out of 13 (54%) tumours, with no relationship in the expression of these genes.
Immunohistochemistry and Western analysis indicated downregulation of ADAMTS-8 protein in 477% tumours. Methylation-
specific PCR analysis of ADAMTS-8 indicated promoter hypermethylation in one out of 24 brain tumours (a metastasis) and three out
of four glioma cell lines suggesting an alternative mechanism of downregulation. These data suggest a role for ADAMTS-8 in brain
tumorigenesis, warranting further investigation into its role in regulation of tumour angiogenesis and local invasion.
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The ADAMs and ADAMTS gene families encode related proteins
characterised by an ADAM-like protease domain (ad isintegrin
and metalloprotease), and distinguished by one or more throm-
bospondin motifs (TS) in ADAMTS (review by Porter et al, 2005).
The ADAMTS genes have varying functions, including inhibition
of angiogenesis (-TS-1, -TS-8)(Vazquez et al, 1999), cleavage of the
matrix proteoglycans aggrecan, versican and brevican (-TS-1, -4,
-5, -8 and -15)(AKA the ‘aggrecanases’)(Matthews et al, 2000;
Collins-Racie et al, 2004; Porter et al, 2005), collagen processing
(TS-2, -3 and -14)(Colige et al, 1995; Colige et al, 1997; Fernandes
et al, 2001; Wang et al, 2004) and blood coagulation homeostasis
(TS-13)(Zheng et al, 2001). The ADAMTS proteins are secreted
proteases, some of which bind to the extracellular matrix (ECM),
unlike the ADAMs proteases that are mostly transmembrane
proteins. ECM binding, substrate recognition and cleavage are
mediated through the central and C-terminal TS repeats and the
spacer region (Kuno and Matsushima, 1998; Tortorella et al, 2000).
ADAMTS-8 and TS-1 are the only two members of the ADAMTS
family known to have antiangiogenic properties. They have been
shown to specifically inhibit endothelial cell (EC) proliferation in
vitro, suppress FGF-2-induced vascularisation in the cornea pocket
assay, and inhibit VEGF-induced angiogenesis in the chorioallan-
toic membrane (CAM) assay (Vazquez et al, 1999). In addition,
ADAMTS-1 can bind VEGF165, limiting its bioavailability; this
binding is mediated by the C-terminal region of ADAMTS-1
(Luque et al, 2003). The function of VEGF on ECs is thus
negatively modulated, and VEGF165, once bound, is unable to
activate its receptor (VEGFR2).
In contrast to ADAMTS-1, ADAMTS-8 has a narrow tissue
distribution and human normal tissue showing moderate to high
levels includes adult and foetal lung, aorta, brain, foetal heart,
foetal kidney, appendix and bladder; both genes are expressed in
adult human normal brain (Vazquez et al, 1999; Collins-Racie et al,
2004). There is evidence of modulation of expression of several of
the ADAMTS genes in cancer, with significant downregulation
(two-fold or lower) of ADAMTS-8 in non-small-cell lung cancer
(NSCLC) (Heighway et al, 2002; Dunn et al, 2004) and
hypermethylation of the promoter region being a possible
mechanism of gene silencing (Dunn et al, 2004). In comparison
to non-neoplastic mammary tissue ADAMTS-8 mRNA is also
significantly downregulated in breast carcinomas (Porter et al,
2004). In contrast, ADAMTS-4 (aggrecanase-1) and TS-5 (aggreca-
nase-2) are upregulated in glioblastomas (GBMs), with a possible
role in increased degradation of brevican thereby increasing
invasive potential (Nakada et al, 2005; Held-Feindt et al, 2006).
Glioblastomas remain one of the most lethal neoplasms, due in
part to their invasive nature and striking resistance to current
therapies. There is currently a quest for a greater understanding of
the biology of angiogenesis and invasion in gliomas with a view to
the discovery of antiangiogenic/anti-invasive molecules that could
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sbe of therapeutic use in prolonging survival. ADAMTS-8 protein
has a more powerful antiangiogenic effect than thrombospondin-1
(TSP1) or endostatin (Vazquez et al, 1999). The aim of this study
was to investigate the expression of ADAMTS-8 in high-grade
gliomas and other brain tumours, and compare this with the
expression of other well-characterised angiogenesis related genes
TSP1 and VEGF.
MATERIALS AND METHODS
Tissues and cell lines
Snap frozen tumour tissue for 41 resected brain tumours
comprising 25 high-grade gliomas (20 glioblastoma WHO grade
IV (GBM), two oligoastrocytoma WHO grade III (OAIII), one
oligodendroglioma WHO grade III (OIII), one astrocytoma WHO
grade III (AIII), one ependymoma WHO grade III (EIII)), five
meningiomas WHO grade I, nine metastases, one haemangio-
blastoma, one medulloblastoma and one sample of non-neoplastic
temporal lobe (from epilepsy surgery) were obtained for analysis
from the Walton Centre for Neurology and Neurosurgery, Liver-
pool with full ethical approval. Intrinsic brain tumours were
diagnosed according to the WHO histopathology classification
(Kleihues and Sobin, 2000). For each case, one whole frozen
tumour tissue fragment (B0.5cm
3) was cut on a cryostat as
follows: 10 30mM sections cut for extraction of RNA/DNA/
protein, followed by a 5mM section for H&E staining and
pathological examination. All tumours were confirmed to contain
at least 70% neoplastic cells.
Normal brain total RNAs were purchased from BD Biosciences
(whole brain), and AMS Biotechnology (cerebellum, cerebral
cortex, cerebral meninges and frontal lobe). Normal brain DNAs
from two separate donors were purchased from AMS Biotechnol-
ogy. A non-neoplastic temporal lobe sample (from epilepsy
surgery) was used in the Western and methylation analysis.
Four glioma cell lines U373, T98G, Hs683 and U87MG used in
the RT–polymerase chain reaction (PCR) and methylation assays
were obtained from ECACC and ATCC.
Genomic DNA extraction
Genomic DNA was extracted from 10 30mM tissue sections using
the Qiagen DNeasyt Tissue kit according to the manufacturer’s
instructions.
Genomic DNA was extracted from cell lines using the Nucleon
BACC1 kit according to the manufacturer’s instructions.
RNA extraction and cDNA synthesis
Total RNA was extracted from 10 30mm frozen tissue sections
using the Qiagen
s Rneasy Mini RNA extraction kit, following the
manufacturer’s protocol. RNA was aliquotted into 1–2mg amounts
for subsequent Dnase treatment using Invitrogen Dnase I
Amplification Grade. cDNA synthesis was performed in 20ml
reactions using Invitrogen Superscriptt Reverse Transcriptase
(RT), and oligo-dT primers (Invitrogen). For each sample, 500ng
of RNA was used for cDNA synthesis and the remaining 500ng for
a negative control (no RT). All new cDNA samples were diluted
20  then 5ml of this dilution was amplified using cDNA specific
PCR primers for the b-actin housekeeping gene to verify successful
reverse transcription of sample cDNA with no genomic contam-
ination (indicated by PCR product size).
Quantitative (real-time) PCR
Quantitative PCR (qPCR) assay of ADAMTS-8 expression in whole
brain, cerebral cortex, frontal lobe, cerebellum, meninges and lung
was undertaken to assess normal levels of the mRNA. Threshold
cycles (Cts) were similar in all the brain regions tested therefore we
used whole brain as the calibrator tissue in all subsequent qRT–
PCR experiments. For comparison, the expression of thrombos-
pondin-1 (TSP1) and vascular endothelial growth factor (VEGF)
was studied in a subset of cases (n¼26, n¼24, respectively).
To compare the relative expression levels of ADAMTS-8, TSP1
and VEGF in normal whole brain to levels in multiple brain
tumour tissues, we have used the comparative Ct method (Livak
and Schmittgen, 2001) in which the expression of the test gene and
a selected endogenous control gene (Histone H3) are measured in
separate tubes. Normal whole brain cDNA was used as the
calibrator tissue in each qPCR, which was carried out in an iCycler
machine (BioRad). All PCR reactions were carried out in triplicate
and each experiment was repeated at least once.
The threshold of detection for all primers was such that product
could be detected from an initial RNA target of 50ng in the RT
reaction. Primer sequences, positions and efficiencies were as
follows. ADAMTS-8 primers spanned exons 3 and 4 (forward: 50
AAC AAA AGC TGC TCC GTG AT-30; reverse: 50-TCT GGT TCA
GGT GGA CGA AC-30); TSP1 primers spanned exons 22 and 23
(forward: 50AGC AGG GTG CTA TTG TGA GG 30; reverse: 50CCT
TAG TGC TTT GGC CTC TG-30); VEGF primers spanned exons 3
and 4 (forward: 50AGA AGG AGG AGG GCA GAA TC-30; reverse: 50
CAC ACA GGA TGG CTT GAA GA) to detect all VEGF isoforms ;
Histone H3 primers spanned exons 3 and 4 (forward: 50
CCACTGAACTTCTGATTCGC-30; reverse: 50 AAGACATCCAGCTA
GCACGC-30). Twenty microlitres of PCR reactions contained 5ml
of 20  diluted cDNA (equivalent to B6.25ng of starting RNA),
10mlI Q t SYBR
s Green Supermix Buffer, 2ml forward and reverse
primers (20pmol/ml) and 3ml ddH2O. cDNA was amplified under
the following conditions: 951C for 3min, followed by 48 cycles of
941C for 30s, Tm (ADAMTS-8, TSP1¼681C, VEGF¼641C) for
30s, 721C for 30s and a final step at 951C for 30s followed by
collection of melt curve data under standard settings. Finally, 5ml
of the resulting PCR product was visualised by electrophoresis
through a 3% agarose gel containing ethidium bromide. Melt
curves for the qPCR reactions and a single band of the correct size
on the gels were used to verify the correct product in each PCR. In
addition, the ADAMTS-8 sequence in normal whole brain, lung
and four brain tumours was verified by direct sequencing of the
PCR product and BLAST analysis. Where mRNA expression data is
described, downregulation has been designated 0.5  or less, and
upregulation as 2  or more.
Immunohistochemical analysis of ADAMTS-8
Immunohistochemistry (IHC) was performed as described pre-
viously (Dunn et al, 2004) using an ADAMTS-8 N-terminal
antibody (1:500 dilution) (ADAMTS-8 AB-1, Oncogene Research
Products; cat#PC508) and 5mm sections cut from formalin fixed,
paraffin-embedded blocks from the same tumour resections. Each
run included tissue sections from brain tumours, normal
cerebellum and a positive control (normal human stomach)
incubated with primary antibody, and a negative control with no
primary antibody for each section. Protein expression was scored
by a consultant neuropathologist (DDP) blinded to clinical details
for each case; each section was assessed as to the type of cells
staining, intracellular distribution and intensity of staining.
Intensity was defined as negative ( ), equivocal (þ/ ), or
positive (with 410% neoplastic cells staining, þ, þþ and
þþþ). Downregulation of ADAMTS-8 compared to cerebellum
is indicated by scores of  , þ/  and þ.
Total protein extraction
A4–5m m
3 piece of brain tissue was homogenised on ice in 100ml
extraction buffer (1 M Tris-HCl pH 7.5, 1.5 M NaCl, 10% SDS, 5%
NP40) containing one Protease Inhibitor tablet per ml buffer
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shaken at 3000r.p.m. at room temperature for 30min before
centrifugation at 13000r.p.m. for 10min. Protein supernatants
were combined with laemmli sample buffer (Bio Rad) heated at
1001C for 10min then plunged into ice immediately prior to gel
electrophoresis.
Western blot analysis of ADAMTS-8
Total protein extracts (SW480¼6mg, non-neoplastic temporal
lobe¼10mg, tumours¼30mg) were separated on 8% Tris-HEPES-
SDS precast polyacrylamide gels (Pierce Preciset Protein Gels,
Perbio Science UK Ltd, Northumberland, UK). Each gel was
divided into two halves (A and B), where both portions received an
identical sample loading and where B subsequently served as a
negative control blot, being incubated in blocking buffer without
primary antibody. Gels were equilibrated in renaturation buffer
(50mM Tris-HCl pH 7.4, 20% glycerol) for 1h prior to transfer.
Proteins were then electrophoretically transferred to a nitrocellu-
lose membrane, which was subsequently incubated overnight in
blocker (PBS-T, 5% Marvel) at room temperature with shaking.
Immunoreactive products were then detected by incubating for 1h
with ADAMTS-8 antibody (1:1000 dilution in blocker). Mem-
branes were incubated for 1h with a 1:3000 dilution (in blocker)
of secondary antibody (HRP labelled anti-rabbit raised in donkey,
Amersham NA 934VS), followed by chemiluminescent detection of
specific proteins using Amersham ECL Advance kit and standard
autoradiography procedures.
Methylation analysis of the ADAMTS-8 promoter region
One microgram of genomic DNA was chemically modified by
treatment with sodium bisulphite using the CpGenomet DNA
modification kit from Intergen (Intergen Company, Oxford, OX4
4GA, UK, Catalog#S7820) according to the kit protocol. The
modified, cleaned DNA was resuspended in 50ml TE buffer,
aliquotted and stored at  801C. A cMSP assay was used to assess
the methylation status of the ADAMTS-8 promoter region as
described previously (Dunn et al, 2004). Polymerase chain reaction
products (control: 299bp, methylation specific: 169bp) were
analysed on 4% agarose gels containing ethidium bromide.
Statistical analysis
Results are expressed as means. Statistical analysis was performed
using SPSS (version 13.0). Differences between groups were
evaluated by the Mann–Whitney test. mRNA and immunocyto-
chemistry data were compared using Spearman’s correlation test.
A probability (P) value o0.05 was considered significant.
RESULTS
ADAMTS-8 expression
mRNA
Non-neoplastic tissues: Gene expression analysis using RT–PCR
showed equivalent levels of ADAMTS-8 in normal whole brain,
frontal lobe, cerebral cortex and meninges, with higher expression
in normal lung (Figure 1).
Brain tumours: Hundred percent of cases showed lower expres-
sion of ADAMTS-8 compared with normal brain. ADAMTS-8 was
not detectable in 14 out of 34 (41%) brain tumours, and
downregulated between two- and a 1000-fold compared to normal
brain in 21 out of 34 (62%) (Figure 1, Table 1). All gliomas showed
at least two-fold downregulation of expression, with eight out of 22
(36%) tumours (all GBM) showing 440-fold downregulation
(Figure 1). Only five grade III gliomas with varying histological
subtypes were available for study, limiting comparison between
different histopathological types of glioma. With the available
series, GBM and grade III gliomas showed an overlapping range of
relative expression of ADAMTS-8 (GBM 0.0001–0.45; grade III
gliomas 0.05–0.3)(Figure 1), and no significant difference between
grades. When analysed separately, both GBMs and grade III
gliomas showed a significant downregulation of ADAMTS-8
compared to the non-neoplastic brain tissues (Mann–Whitney
test: GBM P¼0.001, grade III P¼0.009). ADAMTS-8 was not
detectable in three out of four meningiomas, four out of six
metastases and four out of four glioma cell lines tested (Table 1).
Despite the small number of cases, metastases and meningiomas
were more likely to have lower ADAMTS-8 expression than
gliomas (Mann–Whitney test: metastases P¼0.013, meningiomas
P¼0.031).
Protein
Immunohistochemistry: Immunohistochemistry analysis was
carried out in formalin fixed, paraffin-embedded brain tissues
comprising 35 brain tumours (25 gliomas (20 GBM, five grade III
tumours), seven metastases and three meningiomas) and one
normal cerebellum.
Non-neoplastic brain tissues: Staining in normal stomach sec-
tions, which were used in this study as a positive control, was
punctate and confined to the secretory type cells of the epithelial
layer, as found in normal lung (Dunn et al, 2004). In normal
cerebellum, the Purkinje and molecular cell layers showed focal
cytoplasmic ADAMTS-8 staining of neurons (þþ) (Figure 2A,
Table 1), and in the white matter, astrocytes were positive (þþ)
for ADAMTS-8 protein (Figure 2B).
Brain tumours In tumour sections, some staining was observed
in reactive glia, vascular endothelium and some lymphocytes
(Figure 2C and E). ADAMTS-8 protein in neoplastic cells was
downregulated in the majority of tumours (27 out of 35, 77%)
compared to cerebellum or uninvolved ‘normal’ non-neoplastic
brain present within some tumour sections (Table 1). Most of the
tumours (24 out of 35, 69%) showed some positive diffuse
cytoplasmic staining for ADAMTS-8, with the exception of two
mucinous-type metastases of gastrointestinal origin that showed
focal punctate cytoplasmic staining similar to that seen in
cerebellum, uninvolved brain, stomach and normal lung
(Table 1)(Dunn et al, 2004). One tumour (GBM) was negative for
ADAMTS-8 (Figure 2F, Table 1). Eleven gliomas (11 out of 24,
46%) showed variable nuclear staining (Table 1). Ten tumours
scored þ/ : three GBM, three grade III gliomas, three meningio-
mas and a non-mucinous type metastasis of breast origin (Table 1).
Lung
Non-neoplastic
brain tissues
Glioma cell lines
Other brain tumours
Meningioma
Metastasis
Glioma
0.0 0.5 1.0 1.5
Relative expression of ADAMTS-8
P =0.01
P =0.049
P =0.012
P =0.005
P =0.001
Figure 1 Expression of ADAMTS-8 in brain tissues, glioma cell lines and
lung relative to normal whole brain by quantitative RT–PCR. Grade III
gliomas are indicated by shaded circles.
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(Table 1). Thus 70% GBM, 100% grade III gliomas, 100%
meningiomas and 57% metastases showed decreased expression
of the ADAMTS-8 protein compared to normal brain. There was
no clear correlation between mRNA and immunopositivity
(Spearman Correlation: all cases P¼0.6, gliomas P¼0.109). Eight
tumours (eight out of 35, 23%), all with downregulated mRNA,
showed upregulation or equivalent staining to that in uninvolved
or non-neoplastic brain, including five GBM (with variable nuclear
staining) and three mucinous type metastases of gastrointestinal
origin (Figure 2C–E, Table 1). Of the tumours with no detectable
mRNA, seven out of 11 were immunopositive. Overall, 27 out of 35
(77%) tumours including 20 out of 25 (80%) gliomas were
considered to show downregulation of the protein.
Table 1 Summary of ADAMTS-8 data in brain samples, showing case identifier, histology, expression of mRNA by qRT-PCR, expression of protein by
immunohistochemistry and Western blotting, and the methylation status of the promoter region (methyl)
Protein expression
Immunohistochemistry
Case Histology mRNA C NC N Western Methyl
w brain 1 Normal ¼
cerebel Normal ++F
temp lob Normal ¼ +  
w brain 2 Normal  
w brain 3 Normal  
1 GBM ND +
2 GBM ND ++ +  
3 GBM Down +/  
4 GBM ND +
6 GBM Down     
7 GBM Down +  
8 GBM Down +
9 GBM ND ++ +
11 GBM Down + +
12 GBM Down +/    
13 GBM Down +
15 GBM ND +
28 GBM Down ++
29 GBM Down +
30 GBM Down +
31 GBM Down +
33 GBM Down +/   
35 GBM ++   
37 GBM ++
39 GBM +
5 OAIII Down +
14 OAIII Down +
10 OIII Down +/   
27 AIII Down +/ 
32 EIII Down +/   
Hs683 Glioma CL ND  
T98G Glioma CL ND +
U373 Glioma CL ND +
U87MG Glioma CL ND +
34 haema ND
16 medul ND
17 mening ND +/   
18 mening ND +/   
19 mening ND +/   
20 mening Down
38 mening  
21 met (lung) Down +  
22 met (mel) ND  
23 met (br) ND +/   
24 met (k/pa) ND +  
25 met (GI) Down +++F   
26 met (GI) ND ++  
36 met (GI) +++F NS +
40 met (lung) +  
41 met (lung)  
Expression of mRNA data relative to normal whole brain and was equivalent (¼), not detectable (ND) or downregulated (Down). Immunohistochemistry data show intensity
of staining (  indicates negative; +/ , equivocal; +/++/+++, positive) the subcellular location of the stain (C indicates cytoplasmic; NC, nuclear and cytoplasmic; N, nuclear) and
staining pattern, which was diffuse unless described as focal (F). Western data indicates the presence (+) or absence ( ) of a 98kDa band. Methylation data indicate promoter
hypermethylation (+) or no methylation ( ). w brain¼whole brain; cerebel¼cerebellum; temp lob¼temporal lobe; GBM¼glioblastoma; OA¼oligoastrocytoma;
O¼oligodendroglioma; A¼astrocytoma; E¼ependymoma; haema¼haemangioblastoma; medul¼medulloblastoma; mening¼meningioma; met¼metastatic tumour,
followed by origin of primary tumour – br¼breast; k¼kidney; mel¼melanoma; pa¼pancreas; GI¼gastrointestinal tract; NS¼nonspecific bands.
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non-neoplastic temporal lobe tissue and nine brain tumour total
protein extracts (including five strong expressers of ADAMTS-8 by
IHC analysis, see Table 1) using the same ADAMTS-8 primary
antibody revealed one specific band at B98kDa in the SW480
control, temporal lobe and three glioma extracts (all IHC positive)
(Figure 3, Table 1). A protein loading of three times that of non-
neoplastic brain was required to see any bands from the tumour
extracts. The expected size for ADAMTS-8 using this antibody and
the SW480 protein is 98kDa. No specific bands were detected in
the remaining tumour extracts (Table 1).
Expression of TSP1 and VEGF in brain tumours
mRNA Quantitative RT–PCR analysis showed that both genes
were expressed in all cases, with both TSP1 and VEGF being
differentially expressed compared to normal brain in 62% (16 out
of 26) and 63% (15 out of 24) of cases, respectively (Figure 4).
There was no correlation between the expression patterns of
ADAMTS-8, TSP1 and VEGF. In summary, TSP1 was upregulated
in 42% (11 out of 26), downregulated in 19% (five out of 26) and
unchanged in 38% (10 out of 26) of tumours tested. VEGF was
upregulated in 38% (nine out of 24), downregulated in 25% (six
out of 24) and unchanged in 38% (nine out of 24). In ten tumours
that showed vascular proliferation typical of high-grade gliomas on
examination of the H&E sections, nine also showed up-regulation
of both VEGF and TSP1, accompanied by at least eight-fold
downregulation of ADAMTS-8.
ADAMTS-8 promoter methylation status
There was no evidence of methylation of the ADAMTS-8 promoter
in 23 out of 24 (96%) of the tumours, one out of four cell lines or in
the three normal samples (Table 1). One tumour (a bowel
metastasis) and three out of four glioma cell lines showed
promoter methylation using this assay (Figure 5, Table 1).
DISCUSSION
Brain tumours, especially GBM, have a propensity for diffuse
infiltration of brain parenchyma that contributes to a high
morbidity and mortality. The ability of tumour cells to infiltrate
surrounding brain tissue is reliant on their passage through the
ECM, facilitated in part by the actions of proteases. Similarly,
angiogenesis (also essential to tumour progression) is reliant on
the positive and negative regulation of proteases such as the
MMPs, ADAMs and ADAMTS (review by Handsley and Edwards,
2005).
Until recently, the ADAMs and ADAMTS genes were relatively
understudied in brain tumours (and other cancers), however,
recent reports have suggested roles for ADAMTS-4, TS-5 (Held-
Feindt et al, 2006; Nakada et al, 2005) and ADAM-12 (Kodama
et al, 2004) in GBM, where these proteases are overexpressed. In
contrast, we have shown that the expression of ADAMTS-8 is
downregulated in brain tumours relative to normal brain.
Messenger RNA levels were reduced at least two-fold in 100%
(34 out of 34) tumours and four out of four glioma cell lines tested,
and protein data (IHC and Western) also suggested down-
regulation of ADAMTS-8. IHC analysis indicated decreased levels
of protein in 77% of brain tumours tested compared to non-
neoplastic tissue, and in Western blots, protein was undetectable
in 67% of tumours and indicated a greater threshold of detection
in 33%. Our data are consistent with other reports of ADAMTS-8
downregulation in cancers (Heighway et al, 2002; Dunn et al, 2004;
Porter et al, 2004), suggesting there may be opposing physiological
roles for individual ADAMTS family members in carcinogenesis.
For example the predominant role of ADAMTS-8 may be
A
C
E
B
D
F
Figure 2 Expression of ADAMTS-8 protein by immunohistochemistry
of formalin-fixed, paraffin-embedded brain tissues. (A) Normal cerebellar
cortex (original magnification  400). Positive cytoplasmic staining (þþ)
of neurons in the molecular and Purkinje cell layers. (B) Normal cerebellar
white matter (original magnification  630). Positive cytoplasmic staining
(þþ) of glial cells, most likely astrocytes. (C) and (D) GBM (case no.28).
(C) (original magnification  400) shows positive diffuse cytoplasmic
staining (þ/þþ) of tumour cells (left of image) adherent to a blood
vessel (right side). The tumour cells show cytoplasmic expression and
weaker, variable nuclear expression. The vascular endothelium shows weak
expression and the vascular wall stroma (fibroblast and smooth muscle*)
appears negative. (D) (original magnification  630) shows malignant glial
cells with cytoplasmic and some variable nuclear expression. (E) Metastatic
carcinoma of gastrointestinal tract origin (case no. 25)(original magnification
 400). Strong focal cytoplasmic expression* (þþþ) by malignant
epithelial cells. Adjacent stroma contains fibroblasts (negative), lymphocytes
(weak, variable staining) and vessels (with weak endothelial staining). (F)
GBM case no. 6)(original magnification  630). Negative staining of tumour
cells.
Temporal
100 kDa
75 kDa
Gliomas SW480 Lobe
AB C D E F
Figure 3 Chemiluminescent detection in Western analysis of full-length
ADAMTS-8 protein (98kDa) in total protein tissue extracts from normal
temporal lobe and four GBMs, and commercial total protein extract from
SW480 cell line (human colon carcinoma)(control). Protein loading
amounts: SW480¼15mg, normal brain¼30mg, tumours¼90mg.
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predominant role for ADAMTS-4 and TS-5 may be ECM
degradation necessitating up-regulation. Studies of the MMPs
have shown that some family members act as angiogenic molecules
and some as antiangiogenic (review by Handsley and Edwards,
2005).
The antibody used in this study recognises a binding site within
the prodomain and Western data revealed a 98kDa ADAMTS-8
band common to both tumour and normal brain, consistent with
the size of the full-length secreted protein after removal of the
signal peptide. Using a cDNA probe containing a fragment of
ADAMTS-8 bearing a portion of the disintegrin domain and the
1000
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1
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0.01
0.001
Glioma Medulloblastoma Meningioma Metastasis
Key:
# Not done
* Readings beyond the limits of detection
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Figure 4 Expression of ADAMTS-8, TSP1 and VEGF in brain tumours relative to normal whole brain by quantitative RT–PCR. Y-values are shown on a log
scale where 1 signifies expression equivalent to that observed in normal whole brain.
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Figure 5 Competitive methylation-specific PCR (c-MSP) analysis of brain tumours and glioma cell lines. The presence of the methylation-independent
control fragment (299bp) confirms sufficient amounts of converted DNA in the reaction, while the presence of the methylation-specific product (169bp)
demonstrates the existence of methylated copies of DNA. DNAs from case 36 (metastatic carcinoma of GI origin) and glioma cell lines U373, U87MG and
T98G showed methylation of ADAMTS-8, while cases 10 (OAIII), 2 (GBM), 12 (GBM), 7 (GBM), 18, 19 (meningiomas) and 26 (metastatic tumour of
gastrointestinal/lung origin), and cell line HS683 showed no methylation. C, universally methylated DNA control; M, DNA molecular weight marker.
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sfirst TS-type repeat, positive expression has been demonstrated in
human normal whole brain, and various brain regions (Collins-
Racie et al, 2004). However, other documented forms (79 and
64kDa)(Vazquez et al, 1999) of ADAMTS-8, which retain
antiangiogenic activity after proteolytic cleavage, may be present
in normal and tumour brain tissues, would not be detected in the
present study. ADAMTS-1 processing resulting in the release of the
C-terminal end does not affect the catalytic function of the
protease (Rodriguez-Manzaneque et al, 2000), with both processed
forms having the ability to block EC proliferation in a dose
dependent manner. Moreover, it is suggested that processing
might release two fragments with distinct/independent functions
in the ECM.
IHC data indicated the presence of ADAMTS-8 protein in the
normal cerebellum and lower levels of protein in the majority
(77%) of tumours tested (Table 1). Two mucinous type metastatic
tumours of gastrointestinal origin showed strong staining
(þþþ) for ADAMTS-8, although notably, neither of these cases
gave a specific band in the Western analysis, which could be due to
the lower proportion of ADAMTS-8 expressing cells within these
samples. Most of the gliomas exhibited a diffuse cytoplasmic
staining pattern and in addition 46% showed a variable nuclear
stain. However, the Western data for two out of two samples with
variable nuclear staining showed one band indicating specificity of
the antibody at least under Western conditions. Overall the protein
data for ADAMTS-8 suggest downregulation of the protein in the
majority of brain tumours, although only further experimentation
will determine the precise nature of this ADAMTS-8 protein.
Despite the downregulation of ADAMTS-8 mRNA and protein
seen in the majority of brain tumours studied, there was no clear
correlation between protein and mRNA expression levels. All
tumours had downregulation of mRNA, but this was associated
with varying degrees of immunopositivity. These data may reflect
the differing sensitivities of the RT–PCR and IHC assays, or
suggest that ADAMTS-8 expression may be regulated via
transcription as well as factors that influence protein stability,
with a longer protein half-life in some cases.
The mechanism of downregulation of ADAMTS-8 in these brain
tumours is unknown, but seems unlikely to be hypermethylation of
the promoter region as observed in 58% (29 out of 50) of NSCLC
(Dunn et al, 2004), since only one out of 24 tumours showed
methylation using our assay. Notably, this tumour also showed
hypermethylation in the promoter region of another gene situated
within 20kb on Chr11q25, and it is conceivable that this tumour
contains an extensively methylated region of C11q25. C11q is not a
region commonly showing deletion in LOH or CGH analysis in
gliomas, however, there is evidence (from CGH analysis) of a
550kb-deleted region at 11q13 in low-grade oligodendrogliomas
(Rossi et al, 2005).
No correlation was found in the expression patterns of
ADAMTS-8, TSP1 and VEGF. It has been shown that VEGF is
significantly overexpressed in GBMs (Plate et al, 1992; Shweiki
et al, 1992), meningiomas, metastases and haemangioblastomas,
however our data indicated up-regulation of VEGF in only 38% of
tumours. Munaut et al (2003) found 2–15-fold upregulation of
VEGF mRNA in most (17 out of 20) GBMs, downregulation in two
and equivalent expression in one, although the relative abundance
of isoforms 165, 121, 189 and 145 varied, with 165 being the most
abundant. Since our VEGF PCR primers were designed to detect all
isoforms, the relative abundance of VEGF isoforms in our samples
was not assessed. However, if ADAMTS-8, like its counterpart TS-
1, also binds VEGF165, ADAMTS-8 may sequester VEGF165, thus
exerting an antiangiogenic effect. VEGF expression is upregulated
in regions of hypoxia and localised to tumour vasculature,
and in this study the expression of VEGF was seen in cases
where a vascular proliferation was noted. TSP1 was downregulated
in the minority (19%) of the tumours tested and its expression
did not correlate with that of ADAMTS-8 (also antiangiogenic).
It is known that although some genes involved in angiogenesis
are segregated into proangiogenic or antiangiogenic, the real
situation is far more complex. It has been shown that continuous
expression of the antiangiogenic TSP1 in brain tumours can induce
a more aggressive angiogenic phenotype by inducing VEGF
expression (Filleur et al, 2001; Filleur et al, 2003). In hepatocellular
carcinoma, TSP-1 protein expression (in vivo) is significantly
associated with tumour invasiveness and progression (Poon et al,
2004). Furthermore, in GBM, it has been demonstrated that
tumour perfusion was the same in TSP-1 transfected tumours
and controls, and that although tumour growth in vivo is slowed
by TSP-1 overexpression, tumours still reach a large size
(300mm
3)(Kragh et al, 2002). Moreover, like VEGF, the expression
of TSP1 was coincident with a vascular proliferation in nine
out of 10 tumours. In hepatocellular carcinoma there is a
significant relationship between tumour TSP1 levels and venous
invasion even in patients with high and low tumour VEGF levels
(Poon et al, 2004). It is thought that TSP1 expression in brain
tumours is influenced by several factors including hypoxia, cell
density (in vitro) and cell type (Tenan et al, 2000; Kawataki et al,
2000; Laderoute et al, 2000; Filleur et al, 2001; Naganuma et al,
2003).
The reduction in ADAMTS-8 expression was not tumour type
specific, since 22 gliomas, four meningiomas, six metastases, one
haemangioblastoma and one medulloblastoma were analysed.
However, as yet, the possible role of ADAMTS-8 in brain tumour
development remains unclear. There was no evidence to suggest
that ADAMTS-8 expression is localised to the vasculature as for
TSP1 and VEGF, or whether it is related to hypoxia. ADAMTS-8 is
downregulated in GBM, and further future investigation in low-
grade and anaplastic gliomas that represent the various histolo-
gical subtypes of glioma will reveal whether downregulation is an
early event in gliomagenesis or, as for angiogenesis, may be
associated with the transition from grade II to III.
In summary, the RT–PCR data suggest that in contrast to TSP1
and VEGF, the downregulation of ADAMTS-8 is a consistent event
in the formation of brain tumours and is consistent with findings
in other cancer types. Therefore, insight into its functional role and
the biological events that regulate its expression is warranted.
However, before we can ascertain whether ADAMTS-8 and/or
related molecules represent potential therapeutic targets in
gliomas, further investigation of the ADAMTS gene family will
be necessary to elucidate their potential roles relating to
angiogenesis, ECM degradation and invasion.
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